MD Anderson and the US National Cancer Institute lead the way with a series of recent alliances, highlighted in this special edition of Tech Transfer Roundup focused on oncology.

Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.

IPO Edition: Caribou, AbSci and HCW launched initial public offerings, but three firms that were expected to go public during the week of 19-23 July did not, raising the question of whether investors are beginning to pull back from biopharma offerings.